Eli Lilly drug tirzepatide meets weight-loss goals in obesity trial

A highly anticipated clinical trial from Eli Lilly showed its drug met its primary endpoints for weight loss in obese and overweight study participants. CNBC's Meg Tirrell joins 'Squawk Box' to break down the results.